翰宇药业
(300199)
| 流通市值：211.18亿 | | | 总市值：250.13亿 |
| 流通股本：7.46亿 | | | 总股本：8.83亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 549,442,106.79 | 309,969,965.34 | 590,199,011.64 | 375,225,390.5 |
| 营业收入 | 549,442,106.79 | 309,969,965.34 | 590,199,011.64 | 375,225,390.5 |
| 二、营业总成本 | 407,008,743.17 | 231,507,233.07 | 708,040,579.18 | 459,578,775.38 |
| 营业成本 | 206,243,861.32 | 128,088,503.11 | 253,239,969.55 | 151,708,440.89 |
| 税金及附加 | 5,438,755.44 | 1,642,920.15 | 10,908,974.1 | 6,045,567.47 |
| 销售费用 | 38,968,390.15 | 25,599,623.33 | 119,487,355.75 | 70,260,228.9 |
| 管理费用 | 57,456,563.57 | 29,249,665.17 | 122,446,975.98 | 85,209,042.23 |
| 研发费用 | 46,839,900.41 | 21,707,434.32 | 88,011,064.23 | 59,329,000.15 |
| 财务费用 | 52,061,272.28 | 25,219,086.99 | 113,946,239.57 | 87,026,495.74 |
| 其中:利息费用 | 50,514,918.51 | 25,248,678.11 | 106,499,210.39 | 79,425,721.27 |
| 其中:利息收入 | 198,205.23 | 105,688.7 | 351,393.83 | 191,207.56 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 215,783.62 | -2,261.64 | - | - |
| 加:投资收益 | 936,950.62 | -416,658.98 | 1,545,907.41 | -529,557.23 |
| 资产处置收益 | 552,485.01 | -13,552.73 | 42,783,695.52 | 42,676,324.14 |
| 资产减值损失(新) | -1,411,875.22 | -2,385,683.31 | -108,115,270.24 | 3,465,987.55 |
| 信用减值损失(新) | -2,274,368.27 | -3,825,669.48 | -4,557,398.06 | -5,424,779.04 |
| 其他收益 | 19,587,713.95 | 4,626,081.39 | 24,798,210.54 | 17,937,162.77 |
| 四、营业利润 | 160,040,053.33 | 76,444,987.52 | -161,386,422.37 | -26,228,246.69 |
| 加:营业外收入 | 48,925.06 | 1,404.82 | 484,507.13 | 98,331.8 |
| 减:营业外支出 | 128,125.32 | 100,451.61 | 1,510,344.05 | 1,464,030.72 |
| 五、利润总额 | 159,960,853.07 | 76,345,940.73 | -162,412,259.29 | -27,593,945.61 |
| 减:所得税费用 | 15,441,496.15 | 6,906,915.39 | 17,679,698.64 | 8,234,810.62 |
| 六、净利润 | 144,519,356.92 | 69,439,025.34 | -180,091,957.93 | -35,828,756.23 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 144,519,356.92 | 69,439,025.34 | -180,091,957.93 | -35,828,756.23 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 145,468,616.41 | 69,868,367.53 | -173,654,017.08 | -34,805,639.91 |
| 少数股东损益 | -949,259.49 | -429,342.19 | -6,437,940.85 | -1,023,116.32 |
| 扣除非经常损益后的净利润 | 123,380,468.86 | 65,550,023.23 | -239,652,787.96 | -93,577,678.87 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.16 | 0.08 | -0.2 | -0.04 |
| (二)稀释每股收益 | 0.16 | 0.08 | -0.2 | -0.04 |
| 八、其他综合收益 | -323,282.97 | -99,383.36 | 1,864,588.58 | -713,914.14 |
| 归属于母公司股东的其他综合收益 | -323,282.97 | -99,383.36 | 1,864,588.58 | -713,914.14 |
| 九、综合收益总额 | 144,196,073.95 | 69,339,641.98 | -178,227,369.35 | -36,542,670.37 |
| 归属于母公司股东的综合收益总额 | 145,145,333.44 | 69,768,984.17 | -171,789,428.5 | -35,519,554.05 |
| 归属于少数股东的综合收益总额 | -949,259.49 | -429,342.19 | -6,437,940.85 | -1,023,116.32 |
| 公告日期 | 2025-08-22 | 2025-04-26 | 2025-04-26 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |